Literature DB >> 27440273

Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC-θ in Gastrointestinal Stromal Tumors.

Won Kyu Kim1, SeongJu Yun1, Cheol Keun Park1, Sebastian Bauer2, Jiyoon Kim3, Min Goo Lee3, Hoguen Kim4.   

Abstract

PURPOSE: Tumorigenesis of gastrointestinal stromal tumors (GIST) is driven by gain-of-function mutations in the KIT gene, which result in overexpression of activated mutant KIT proteins (MT-KIT). However, the mechanism of MT-KIT overexpression is poorly understood. EXPERIMENTAL
DESIGN: By protein expression analysis and immunofluorescent microscopic analysis, we determine the stability and localization of MT-KIT in four GIST cell lines with different mutations and HeLa cells transfected with mutant KIT model vectors. We also used 154 human GIST tissues to analyze the relationship between the expression of PKC-θ and MT-KITs, and correlations between PKC-θ overexpression and clinicopathological parameters.
RESULTS: We report that four different MT-KIT proteins are intrinsically less stable than wild-type KIT due to proteasome-mediated degradation and abnormally localized to the endoplasmic reticulum (ER) or the Golgi complex. By screening a MT-KIT-stabilizing factor, we find that PKC-θ is strongly and exclusively expressed in GISTs and interacts with intracellular MT-KIT to promote its stabilization by increased retention in the Golgi complex. In addition, Western blotting analysis using 50 GIST samples shows strong correlation between PKC-θ and MT-KIT expression (correlation coefficient = 0.682, P < 0.000001). Immunohistochemical analysis using 154 GISTs further demonstrates that PKC-θ overexpression significantly correlates with several clinicopathological parameters such as high tumor grade, frequent recurrence/metastasis, and poor patient survival.
CONCLUSIONS: Our findings suggest that sustained MT-KIT overexpression through PKC-θ-mediated stabilization in the Golgi contributes to GIST progression and provides a rationale for anti-PKC-θ therapy in GISTs. Clin Cancer Res; 23(3); 845-56. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27440273     DOI: 10.1158/1078-0432.CCR-16-0521

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor.

Authors:  Leili Ran; Yuedan Chen; Jessica Sher; Elissa W P Wong; Devan Murphy; Jenny Q Zhang; Dan Li; Kemal Deniz; Inna Sirota; Zhen Cao; Shangqian Wang; Youxin Guan; Shipra Shukla; Katie Yang Li; Alan Chramiec; Yuanyuan Xie; Deyou Zheng; Richard P Koche; Cristina R Antonescu; Yu Chen; Ping Chi
Journal:  Cancer Discov       Date:  2017-11-21       Impact factor: 39.397

2.  Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors.

Authors:  SeongJu Yun; Won Kyu Kim; Yujin Kwon; Mi Jang; Sebastian Bauer; Hoguen Kim
Journal:  Int J Cancer       Date:  2018-01-22       Impact factor: 7.396

3.  N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.

Authors:  Yuuki Obata; Yasushi Hara; Isamu Shiina; Takatsugu Murata; Yasutaka Tasaki; Kyohei Suzuki; Keiichi Ito; Shou Tsugawa; Kouhei Yamawaki; Tsuyoshi Takahashi; Koji Okamoto; Toshirou Nishida; Ryo Abe
Journal:  Cell Commun Signal       Date:  2019-09-04       Impact factor: 5.712

Review 4.  Mutations of FLT3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling.

Authors:  Shinichiro Takahashi
Journal:  Leuk Res Rep       Date:  2019-11-27

Review 5.  The Emerging Function of PKCtheta in Cancer.

Authors:  Amandine Nicolle; Ye Zhang; Karine Belguise
Journal:  Biomolecules       Date:  2021-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.